{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:35:39Z","timestamp":1793414139748,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K15778"],"award-info":[{"award-number":["22K15778"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Sleep Med"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44470-026-00164-x","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:38:11Z","timestamp":1788986291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Dual orexin receptor antagonist-assisted dose reduction of benzodiazepines and benzodiazepine receptor agonists: a mirror-image analysis of insurance claims data"],"prefix":"10.1007","volume":"22","author":[{"given":"Kentaro","family":"Matsui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyoshi","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunsuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kurihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Takaesu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7414-9017","authenticated-orcid":false,"given":"Yuichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"2","key":"164_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2188\/jea.10.79","volume":"10","author":"Y Doi","year":"2000","unstructured":"Doi Y, Minowa M, Okawa M, Uchiyama M. Prevalence of sleep disturbance and hypnotic medication use in relation to sociodemographic factors in the general Japanese adult population. J Epidemiol. 2000;10(2):79\u201386. https:\/\/doi.org\/10.2188\/jea.10.79.","journal-title":"J Epidemiol"},{"issue":"2","key":"164_CR2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamapsychiatry.2014.1763","volume":"72","author":"M Olfson","year":"2015","unstructured":"Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiat. 2015;72(2):136\u201342. https:\/\/doi.org\/10.1001\/jamapsychiatry.2014.1763.","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"164_CR3","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4140\/TCP.n.2013.538","volume":"28","author":"JY Wick","year":"2013","unstructured":"Wick JY. The history of benzodiazepines. Consult Pharm. 2013;28(9):538\u201348. https:\/\/doi.org\/10.4140\/TCP.n.2013.538.","journal-title":"Consult Pharm"},{"issue":"2","key":"164_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2125.2012.04418.x","volume":"77","author":"M Lader","year":"2014","unstructured":"Lader M. Benzodiazepine harm: how can it be reduced? Br J Clin Pharmacol. 2014;77(2):295\u2013301. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04418.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"164_CR5","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.mayocp.2016.07.024","volume":"91","author":"M Markota","year":"2016","unstructured":"Markota M, Rummans TA, Bostwick JM, Lapid MI. Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc. 2016;91(11):1632\u20139. https:\/\/doi.org\/10.1016\/j.mayocp.2016.07.024.","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"164_CR6","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M. Treatment of benzodiazepine dependence. N Engl J Med. 2017;376(12):1147\u201357. https:\/\/doi.org\/10.1056\/NEJMra1611832.","journal-title":"N Engl J Med"},{"issue":"5","key":"164_CR7","first-page":"339","volume":"64","author":"K Pottie","year":"2018","unstructured":"Pottie K, Thompson W, Davies S, Grenier J, Sadowski CA, Welch V, et al. Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(5):339\u201351.","journal-title":"Can Fam Physician"},{"issue":"2","key":"164_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/ageing\/afx167","volume":"47","author":"N Treves","year":"2018","unstructured":"Treves N, Perlman A, Kolenberg Geron L, Asaly A, Matok I. Z-drugs and risk for falls and fractures in older adults-a systematic review and meta-analysis. Age Ageing. 2018;47(2):201\u20138. https:\/\/doi.org\/10.1093\/ageing\/afx167.","journal-title":"Age Ageing"},{"issue":"5","key":"164_CR9","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.7150\/ijms.51658","volume":"18","author":"M Toyoshima","year":"2021","unstructured":"Toyoshima M, Noguchi Y, Otsubo M, Tachi T, Teramachi H. Differences in detected safety signals between benzodiazepines and non-benzodiazepine hypnotics: pharmacovigilance study using a spontaneous reporting system. Int J Med Sci. 2021;18(5):1130\u20136. https:\/\/doi.org\/10.7150\/ijms.51658.","journal-title":"Int J Med Sci"},{"key":"164_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102507","volume":"70","author":"J Brandt","year":"2024","unstructured":"Brandt J, Bressi J, L\u00ea ML, Neal D, Cadogan C, Witt-Doerring J, et al. Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review. EClinicalMedicine. 2024;70:102507. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102507.","journal-title":"EClinicalMedicine"},{"issue":"3A","key":"164_CR11","doi-asserted-by":"publisher","first-page":"39S","DOI":"10.1016\/S0002-9343(13)80001-0","volume":"88","author":"T Roehrs","year":"1990","unstructured":"Roehrs T, Vogel G, Roth T. Rebound insomnia: its determinants and significance. Am J Med. 1990;88(3 3A):39S\u201342S. https:\/\/doi.org\/10.1016\/S0002-9343(13)80001-0.","journal-title":"Am J Med"},{"issue":"1","key":"164_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1756-0500-5-684","volume":"5","author":"C Lopez-Peig","year":"2012","unstructured":"Lopez-Peig C, Mundet X, Casabella B, del Val JL, Lacasta D, Diogene E. Analysis of benzodiazepine withdrawal program managed by primary care nurses in Spain. BMC Res Notes. 2012;5(1):684. https:\/\/doi.org\/10.1186\/1756-0500-5-684.","journal-title":"BMC Res Notes"},{"key":"164_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107962","volume":"210","author":"PA Moreno-Gut\u00ederrez","year":"2020","unstructured":"Moreno-Gut\u00ederrez PA, Gaviria-Mendoza A, Ochoa-Orozco SA, Yepes-Echeverri MC, Machado-Alba JE. Long-term users of benzodiazepines in Colombia: patterns of use and cessation of treatment. Drug Alcohol Depend. 2020;210:107962. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.107962.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"164_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13902","volume":"32","author":"C Muehlan","year":"2023","unstructured":"Muehlan C, Roch C, Vaillant C, Dingemanse J. The orexin story and orexin receptor antagonists for the treatment of insomnia. J Sleep Res. 2023;32(6):e13902. https:\/\/doi.org\/10.1111\/jsr.13902.","journal-title":"J Sleep Res"},{"issue":"5","key":"164_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S1474-4422(14)70053-5","volume":"13","author":"D Michelson","year":"2014","unstructured":"Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, et al. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13(5):461\u201371. https:\/\/doi.org\/10.1016\/S1474-4422(14)70053-5.","journal-title":"Lancet Neurol"},{"issue":"9","key":"164_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsaa123","volume":"43","author":"M K\u00e4rpp\u00e4","year":"2020","unstructured":"K\u00e4rpp\u00e4 M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, et al. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43(9):zsaa123. https:\/\/doi.org\/10.1093\/sleep\/zsaa123.","journal-title":"Sleep"},{"issue":"7526","key":"164_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38623.768588.47","volume":"331","author":"J Glass","year":"2005","unstructured":"Glass J, Lanct\u00f4t KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331(7526):1169. https:\/\/doi.org\/10.1136\/bmj.38623.768588.47.","journal-title":"BMJ"},{"issue":"9","key":"164_CR18","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1111\/jgs.19512","volume":"73","author":"AM McEvoy","year":"2025","unstructured":"McEvoy AM, Langford AV, Liau SJ, Goordeen D, Reeve E, Turner JP. Deprescribing benzodiazepine receptor agonists in older adults and people with cognitive impairment: a systematic review. J Am Geriatr Soc. 2025;73(9):2905\u201313. https:\/\/doi.org\/10.1111\/jgs.19512.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"164_CR19","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/pcn.70004","volume":"80","author":"K Kurihara","year":"2026","unstructured":"Kurihara K, Sugiura K, Shimura A, Matsui K, Takagi S, Inoue Y, et al. Higher discontinuation with dual orexin receptor antagonists than with benzodiazepines: a Japanese claims cohort study. Psychiatry Clin Neurosci. 2026;80(3):190\u20135. https:\/\/doi.org\/10.1111\/pcn.70004.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"8","key":"164_CR20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/pcn.12275","volume":"69","author":"T Inada","year":"2015","unstructured":"Inada T, Inagaki A. Psychotropic dose equivalence in Japan. Psychiatry Clin Neurosci. 2015;69(8):440\u20137. https:\/\/doi.org\/10.1111\/pcn.12275.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"8","key":"164_CR21","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.eurpsy.2015.09.003","volume":"30","author":"TA Kurko","year":"2015","unstructured":"Kurko TA, Saastamoinen LK, T\u00e4hk\u00e4p\u00e4\u00e4 S, Tuulio-Henriksson A, Taiminen T, Tiihonen J, et al. Long-term use of benzodiazepines: Definitions, prevalence and usage patterns - a systematic review of register-based studies. Eur Psychiatry. 2015;30(8):1037\u201347. https:\/\/doi.org\/10.1016\/j.eurpsy.2015.09.003.","journal-title":"Eur Psychiatry"},{"issue":"1","key":"164_CR22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12916-020-01821-5","volume":"18","author":"K Richardson","year":"2020","unstructured":"Richardson K, Loke YK, Fox C, Maidment I, Howard R, Steel N, et al. Adverse effects of Z-drugs for sleep disturbance in people living with dementia: a population-based cohort study. BMC Med. 2020;18(1):351. https:\/\/doi.org\/10.1186\/s12916-020-01821-5.","journal-title":"BMC Med"},{"issue":"533","key":"164_CR23","first-page":"958","volume":"56","author":"C Vicens","year":"2006","unstructured":"Vicens C, Fiol F, Llobera J, Campoamor F, Mateu C, Alegret S, et al. Withdrawal from long-term benzodiazepine use: randomised trial in family practice. Br J Gen Pract. 2006;56(533):958\u201363.","journal-title":"Br J Gen Pract"},{"issue":"20","key":"164_CR24","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1001\/archinte.159.20.2456","volume":"159","author":"D Garfinkel","year":"1999","unstructured":"Garfinkel D, Zisapel N, Wainstein J, Laudon M. Facilitation of benzodiazepine discontinuation by melatonin: a new clinical approach. Arch Intern Med. 1999;159(20):2456\u201360. https:\/\/doi.org\/10.1001\/archinte.159.20.2456.","journal-title":"Arch Intern Med"},{"issue":"5","key":"164_CR25","first-page":"189","volume":"54","author":"M Ansseau","year":"1993","unstructured":"Ansseau M, De Roeck J. Trazodone in benzodiazepine dependence. J Clin Psychiatry. 1993;54(5):189\u201391.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"164_CR26","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/YIC.0000000000000450","volume":"38","author":"H Hori","year":"2023","unstructured":"Hori H. Successful treatment of switching from benzodiazepine to orexin receptor antagonists improves cognitive function in psychiatric disorders: four case reports. Int Clin Psychopharmacol. 2023;38(3):192\u20134. https:\/\/doi.org\/10.1097\/YIC.0000000000000450.","journal-title":"Int Clin Psychopharmacol"},{"issue":"10","key":"164_CR27","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.5664\/jcsm.10668","volume":"19","author":"S Horikoshi","year":"2023","unstructured":"Horikoshi S, Miura I, Suzuki Y, Kobayashi Y, Hirata Y, Goto M, et al. Switching to lemborexant for the management of insomnia in mental disorders: the SLIM study. J Clin Sleep Med. 2023;19(10):1753\u20138. https:\/\/doi.org\/10.5664\/jcsm.10668.","journal-title":"J Clin Sleep Med"},{"issue":"3","key":"164_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2868","volume":"38","author":"K Okino","year":"2023","unstructured":"Okino K, Suzuki H, Tomioka H, Sanada K, Kawai K, Iwanami A, et al. Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma-aminobutyric acid-benzodiazepine receptor agonists or suvorexant. Hum Psychopharmacol. 2023;38(3):e2868. https:\/\/doi.org\/10.1002\/hup.2868.","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"164_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.5664\/jcsm.10946","volume":"20","author":"M Tachibana","year":"2024","unstructured":"Tachibana M, Kanahara N, Oda Y, Hasegawa T, Kimura A, Iyo M. A retrospective clinical practice study comparing the usefulness of dual-orexin receptor antagonists and a melatonin receptor agonist in patients switching from long-term benzodiazepine receptor agonists. J Clin Sleep Med. 2024;20(4):603\u201313. https:\/\/doi.org\/10.5664\/jcsm.10946.","journal-title":"J Clin Sleep Med"},{"issue":"4","key":"164_CR30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.9758\/cpn.25.1292","volume":"23","author":"N Kanahara","year":"2025","unstructured":"Kanahara N, Tachibana M, Oda Y, Hasegawa T, Kimura A, Iyo M. Successful methods for switching from a benzodiazepine receptor agonist to a dual orexin receptor antagonist for the treatment of insomnias. Clin Psychopharmacol Neurosci. 2025;23(4):713\u20138. https:\/\/doi.org\/10.9758\/cpn.25.1292.","journal-title":"Clin Psychopharmacol Neurosci"},{"issue":"4","key":"164_CR31","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1007\/s12325-024-02811-2","volume":"41","author":"M Ozone","year":"2024","unstructured":"Ozone M, Hirota S, Ariyoshi Y, Hayashida K, Ikegami A, Habukawa M, et al. Efficacy and safety of transitioning to lemborexant from z-drug, suvorexant, and ramelteon in Japanese insomnia patients: an open-label, multicenter study. Adv Ther. 2024;41(4):1728\u201345. https:\/\/doi.org\/10.1007\/s12325-024-02811-2.","journal-title":"Adv Ther"},{"issue":"10","key":"164_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11920-016-0727-9","volume":"18","author":"G Airagnes","year":"2016","unstructured":"Airagnes G, Pelissolo A, Lavall\u00e9e M, Flament M, Limosin F. Benzodiazepine misuse in the elderly: risk factors, consequences, and management. Curr Psychiatry Rep. 2016;18(10):89. https:\/\/doi.org\/10.1007\/s11920-016-0727-9.","journal-title":"Curr Psychiatry Rep"},{"issue":"4","key":"164_CR33","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1176\/ajp.146.4.529","volume":"146","author":"E Schweizer","year":"1989","unstructured":"Schweizer E, Case WG, Rickels K. Benzodiazepine dependence and withdrawal in elderly patients. Am J Psychiatry. 1989;146(4):529\u201331. https:\/\/doi.org\/10.1176\/ajp.146.4.529.","journal-title":"Am J Psychiatry"},{"issue":"6 Suppl 1","key":"164_CR34","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.jped.2015.08.006","volume":"91","author":"ML Nunes","year":"2015","unstructured":"Nunes ML, Bruni O. Insomnia in childhood and adolescence: clinical aspects, diagnosis, and therapeutic approach. J Pediatr (Rio J). 2015;91(6 Suppl 1):S26-35. https:\/\/doi.org\/10.1016\/j.jped.2015.08.006.","journal-title":"J Pediatr (Rio J)"},{"key":"164_CR35","doi-asserted-by":"publisher","first-page":"1174719","DOI":"10.3389\/fpsyt.2023.1174719","volume":"14","author":"K Futenma","year":"2023","unstructured":"Futenma K, Takaesu Y, Komada Y, Shimura A, Okajima I, Matsui K, et al. Delayed sleep-wake phase disorder and its related sleep behaviors in the young generation. Front Psychiatry. 2023;14:1174719. https:\/\/doi.org\/10.3389\/fpsyt.2023.1174719.","journal-title":"Front Psychiatry"},{"key":"164_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.spen.2023.101076","volume":"47","author":"K Singh","year":"2023","unstructured":"Singh K, Zimmerman AW. Sleep in autism spectrum disorder and attention deficit hyperactivity disorder. Semin Pediatr Neurol. 2023;47:101076. https:\/\/doi.org\/10.1016\/j.spen.2023.101076.","journal-title":"Semin Pediatr Neurol"},{"key":"164_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.sleep.2016.04.011","volume":"25","author":"A Shimura","year":"2016","unstructured":"Shimura A, Takaesu Y, Aritake S, Futenma K, Komada Y, Inoue Y. Later sleep schedule and depressive symptoms are associated with usage of multiple kinds of hypnotics. Sleep Med. 2016;25:56\u201362. https:\/\/doi.org\/10.1016\/j.sleep.2016.04.011.","journal-title":"Sleep Med"},{"key":"164_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.sleep.2024.08.006","volume":"122","author":"A Shimura","year":"2024","unstructured":"Shimura A, Takaesu Y, Sugiura K, Takagi S, Okawa Y, Inoue Y. Factors associated with hypnotics polypharmacy in the Japanese population. Sleep Med. 2024;122:99\u2013105. https:\/\/doi.org\/10.1016\/j.sleep.2024.08.006.","journal-title":"Sleep Med"},{"issue":"10","key":"164_CR39","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/17512433.2025.2573364","volume":"18","author":"Y Inoue","year":"2025","unstructured":"Inoue Y, Koebis M. Comprehensive understanding of the treatment of insomnia with lemborexant. Expert Rev Clin Pharmacol. 2025;18(10):1\u201312. https:\/\/doi.org\/10.1080\/17512433.2025.2573364.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"164_CR40","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jpsychires.2020.05.025","volume":"128","author":"T Kishi","year":"2020","unstructured":"Kishi T, Nomura I, Matsuda Y, Sakuma K, Okuya M, Ikuta T, et al. Lemborexant vs suvorexant for insomnia: a systematic review and network meta-analysis. J Psychiatr Res. 2020;128:68\u201374. https:\/\/doi.org\/10.1016\/j.jpsychires.2020.05.025.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"164_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-025-03439-8","volume":"15","author":"T Kishi","year":"2025","unstructured":"Kishi T, Ikuta T, Citrome L, Sakuma K, Hatano M, Hamanaka S, et al. Comparative efficacy and safety of daridorexant, lemborexant, and suvorexant for insomnia: a systematic review and network meta-analysis. Transl Psychiatry. 2025;15(1):211. https:\/\/doi.org\/10.1038\/s41398-025-03439-8.","journal-title":"Transl Psychiatry"},{"key":"164_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1175372","volume":"14","author":"T Xue","year":"2023","unstructured":"Xue T, Wu X, Li J, Chen S, Wang Z, Tan X, et al. Different doses of dual orexin receptor antagonists in primary insomnia: a Bayesian network analysis. Front Pharmacol. 2023;14:1175372. https:\/\/doi.org\/10.3389\/fphar.2023.1175372.","journal-title":"Front Pharmacol"}],"container-title":["Journal of Clinical Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44470-026-00164-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44470-026-00164-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44470-026-00164-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:38:12Z","timestamp":1788986292000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44470-026-00164-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["164"],"URL":"https:\/\/doi.org\/10.1007\/s44470-026-00164-x","relation":{},"ISSN":["1550-9389","1550-9397"],"issn-type":[{"value":"1550-9389","type":"print"},{"value":"1550-9397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"3 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was granted an exemption from ethical approval by the institutional review board of the Neuropsychiatric Research Institute (Protocol Number: #247) because it did not involve identifiable personal information or biological samples. Informed consent was waived due to the anonymous nature of the data. All procedures were conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.M. received lecture fees from Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Japan Blood Products Organization, Lundbeck Japan, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Mochida Pharmaceutical, MSD, Nobel Pharma, Otsuka Pharmaceutical, Sumitomo Pharma, Takeda Pharmaceutical, and Viatris Pharmaceuticals, and consulting fees from Eisai, outside the submitted work. A.S. received lecture fees from Eisai and MSD, outside the submitted work. Y.T. received lecture fees from Takeda Pharmaceutical, Otsuka Pharmaceutical, Daiichi Sankyo Company, Shionogi, Mochida Pharmaceutical, Lundbeck Japan, Eisai, MSD, and Viatris Pharmaceuticals, outside the submitted work. Y.I. received lecture fees from Astellas Pharma, Eisai, Shionogi, and Takeda Pharmaceutical; consulting and advisory fees from Eisai, Taisho Pharmaceutical, and Viatris Pharmaceuticals; and research funding from Koike Medical, Philips Japan, and Teijin Pharma. The Department of Somnology at Tokyo Medical University is an endowment department supported by an unrestricted grant. The other authors declare no additional conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"163"}}